SCHEMBL101460

SCHEMBL101460

N#CC1(CO)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126698 0.88
SCHEMBL101752 0.88
SCHEMBL6222795 0.86 ALDH1A1 (0.46)
SCHEMBL31392705 0.83
SCHEMBL4243647 0.82
SCHEMBL14728239 0.82
SCHEMBL1565996 0.82 DPP4 (0.37)
SCHEMBL24711335 0.82 ALDH1A1 (0.31)
Hydrochloric Acid SCHEMBL14716385 0.80
SCHEMBL25728476 0.78 OPRM1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US claimed
WO-2022013417-A1 PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS SYNGENTA CROP PROTECTION AG (CH) 2022-01-20 WO claimed
WO-2021105117-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO claimed
EP-1869032-B1 PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2008-08-13 EP claimed
US-20080167297-A1 Pyrimidine Derivatives for Use as Anticancer Agents ASTRAZENECA AB (SE) 2008-07-10 US claimed
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 US disclosed
EP-4702027-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2026-03-04 EP disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
EP-4680609-A1 KRAS MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 US disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 US disclosed
US-20260008789-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS INC (US) 2026-01-08 US disclosed
EP-1165562-A1 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES Cephalon, Inc. (US) 2002-01-02 EP disclosed
WO-2000047583-A9 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES CEPHALON INC (US) 2001-09-20 WO disclosed
EP-0748800-B1 Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists HOFFMANN LA ROCHE (CH) 2001-05-09 EP disclosed
WO-2000047583-A1 CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES CEPHALON, INC. (US) 2000-08-17 WO disclosed
US-5859014-A USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA SYNTEX (U.S.A.) INC. (US) 1999-01-12 US disclosed
EP-0748800-A2 Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1996-12-18 EP disclosed
EP-0306440-A2 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents SCHERING AKTIENGESELLSCHAFT (DE) 1989-03-08 EP disclosed
EP-0148004-A2 Cephalosporin antibiotics GLAXO GROUP LIMITED (GB) 1985-07-10 EP disclosed